Royal North Shore Hospital, St Leonards, NSW
I thought it is worthwhile to highlight recent news about dismal HBA1C levels in both the US and Australia which also may be reflective of levels in the UK. “Despite the availability of newer insulin analogs and increased use of insulin pumps and CGMs in the U.S., the mean A1c levels for patients with type 1 diabetes have increased in the past 5 years and only 1 out 5 patients reach ADA target A1c levels," says DTT Editor-in-Chief and co-author of the article, Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora). "Above all these data represent 30,000 patients followed at the leading centers in the U.S."
This research is fascinating in terms of the questions the data raises for DAFNE members. For me personally, having up to six needles a day and testing up to 10 times I have high expectations that my HBA1C will be 7 or below. However if these results of only 20% achieving their HBA1C of the American study above, are also reflecting DAFNE members, should we question the efficacy of our routines or on the other hand has there been any studies showing that DAFNE members achieve more consistent and lower Blood Glucose levels than their diabetic counterparts?
It is also interesting that with all the new apps available on Apple and google play there has been a lack of research or scientific analysis of how effective these apps are in reducing HBA1C. This is of great concern for diabetics putting their trust into using
apps that in reality may be ineffective or lead to problems in personal management. “https://www.mja.com.au/system/files/issues/209_10/10.5694mja18.00066.pdf”